CHROM	POS	ID	REF	ALT	QUAL	FILTER	FORMAT	D21_46860_648251_293574_Lung_S1	NM_Transcript	Allele	Consequence	IMPACT	SYMBOL	Gene	Feature_type	Feature	BIOTYPE	EXON	INTRON	HGVSc	HGVSp	cDNA_position	CDS_position	Protein_position	Amino_acids	Codons	Existing_variation	DISTANCE	STRAND	FLAGS	VARIANT_CLASS	SYMBOL_SOURCE	HGNC_ID	CANONICAL	MANE	MANE_SELECT	MANE_PLUS_CLINICAL	TSL	APPRIS	CCDS	ENSP	SWISSPROT	TREMBL	UNIPARC	UNIPROT_ISOFORM	SOURCE	GENE_PHENO	SIFT	PolyPhen	DOMAINS	miRNA	HGVS_OFFSET	AF	AFR_AF	AMR_AF	EAS_AF	EUR_AF	SAS_AF	gnomADe_AF	gnomADe_AFR_AF	gnomADe_AMR_AF	gnomADe_ASJ_AF	gnomADe_EAS_AF	gnomADe_FIN_AF	gnomADe_MID_AF	gnomADe_NFE_AF	gnomADe_REMAINING_AF	gnomADe_SAS_AF	gnomADg_AF	gnomADg_AFR_AF	gnomADg_AMI_AF	gnomADg_AMR_AF	gnomADg_ASJ_AF	gnomADg_EAS_AF	gnomADg_FIN_AF	gnomADg_MID_AF	gnomADg_NFE_AF	gnomADg_REMAINING_AF	gnomADg_SAS_AF	MAX_AF	MAX_AF_POPS	CLIN_SIG	SOMATIC	PHENO	PUBMED	MOTIF_NAME	MOTIF_POS	HIGH_INF_POS	MOTIF_SCORE_CHANGE	TRANSCRIPTION_FACTORS	SpliceAI_cutoff	SpliceAI_pred_DP_AG	SpliceAI_pred_DP_AL	SpliceAI_pred_DP_DG	SpliceAI_pred_DP_DL	SpliceAI_pred_DS_AG	SpliceAI_pred_DS_AL	SpliceAI_pred_DS_DG	SpliceAI_pred_DS_DL	SpliceAI_pred_SYMBOL	REVEL	LOEUF	ClinVar	ClinVar_AF_ESP	ClinVar_AF_EXAC	ClinVar_AF_TGP	ClinVar_ALLELEID	ClinVar_CLNDN	ClinVar_CLNDNINCL	ClinVar_CLNDISDB	ClinVar_CLNDISDBINCL	ClinVar_CLNHGVS	ClinVar_CLNREVSTAT	ClinVar_CLNSIG	ClinVar_CLNSIGCONF	ClinVar_CLNSIGINCL	ClinVar_CLNSIGSCV	ClinVar_CLNVC	ClinVar_CLNVCSO	ClinVar_CLNVI	ClinVar_DBVARID	ClinVar_GENEINFO	ClinVar_MC	ClinVar_ONCDN	ClinVar_ONCDNINCL	ClinVar_ONCDISDB	ClinVar_ONCDISDBINCL	ClinVar_ONC	ClinVar_ONCINCL	ClinVar_ONCREVSTAT	ClinVar_ONCSCV	ClinVar_ONCCONF	ClinVar_ORIGIN	ClinVar_RS	ClinVar_SCIDN	ClinVar_SCIDNINCL	ClinVar_SCIDISDB	ClinVar_SCIDISDBINCL	ClinVar_SCIREVSTAT	ClinVar_SCI	ClinVar_SCIINCL	ClinVar_SCISCV	CIViC	CIViC_GN	CIViC_VT	CIViC_CSQ	CancerHotspots	CancerHotspots_HOTSPOT	CancerHotspots_HOTSPOT_GENE	CancerHotspots_HOTSPOT_HGVSp	CancerHotspots_HOTSPOT3D	CancerHotspots_HOTSPOT3D_GENE	CancerHotspots_HOTSPOT3D_HGVSp	CancerHotspots_HOTSPOTNC	CancerHotspots_HOTSPOTNC_GENE	CancerHotspots_HOTSPOTNC_HGVSc	BND_DEPTH	CIEND	CIPOS	DP	DUPHOMLEN	DUPHOMSEQ	DUPSVLEN	FractionInformativeReads	HOMLEN	HOMSEQ	IMPRECISE	LEFT_SVINSSEQ	MATEID	MATE_BND_DEPTH	MQ	ONCOKB_DATA_VERSION	ONCOKB_EFFECT	ONCOKB_GENE_EXIST	ONCOKB_GENE_SUMMARY	ONCOKB_HOTSPOT	ONCOKB_JSON	ONCOKB_LAST_UPDATE	ONCOKB_ONCOGENIC	ONCOKB_QUERY_TYPE	ONCOKB_TUMOR_TYPE_SUMMARY	ONCOKB_VARIANT_EXIST	ONCOKB_VARIANT_SUMMARY	OriginalContig	OriginalStart	RIGHT_SVINSSEQ	SVLEN	SVTYPE	hotspot
chr1	11127682	.	G	A	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:38.18:0,4:1:0,0:0,4:4:GGG:0,0,4,0:0,0,0,4	NM_004958	A	missense_variant	MODERATE	MTOR	ENSG00000198793	Transcript	ENST00000361445	protein_coding	44/58		ENST00000361445.9:c.6158C>T	ENSP00000354558.4:p.Pro2053Leu	6279	6158	2053	P/L	cCc/cTc	rs1642911129		-1		SNV	HGNC	HGNC:3942	YES	MANE_Select	NM_004958.4		1	P1	CCDS127.1	ENSP00000354558	P42345.237		UPI000012ABD3			1	deleterious_low_confidence(0)		PDB-ENSP_mappings:1aue.A&PDB-ENSP_mappings:1aue.B&PDB-ENSP_mappings:1fap.B&PDB-ENSP_mappings:1nsg.B&PDB-ENSP_mappings:2fap.B&PDB-ENSP_mappings:2gaq.A&PDB-ENSP_mappings:2npu.A&PDB-ENSP_mappings:2rse.B&PDB-ENSP_mappings:3fap.B&PDB-ENSP_mappings:3jbz.A&PDB-ENSP_mappings:4drh.B&PDB-ENSP_mappings:4drh.E&PDB-ENSP_mappings:4dri.B&PDB-ENSP_mappings:4drj.B&PDB-ENSP_mappings:4fap.B&PDB-ENSP_mappings:4jsn.A&PDB-ENSP_mappings:4jsn.B&PDB-ENSP_mappings:4jsp.A&PDB-ENSP_mappings:4jsp.B&PDB-ENSP_mappings:4jsv.A&PDB-ENSP_mappings:4jsv.B&PDB-ENSP_mappings:4jsx.A&PDB-ENSP_mappings:4jsx.B&PDB-ENSP_mappings:4jt5.A&PDB-ENSP_mappings:4jt5.B&PDB-ENSP_mappings:4jt6.A&PDB-ENSP_mappings:4jt6.B&PDB-ENSP_mappings:5flc.B&PDB-ENSP_mappings:5flc.F&PDB-ENSP_mappings:5gpg.B&PDB-ENSP_mappings:5h64.A&PDB-ENSP_mappings:5h64.a&PDB-ENSP_mappings:5wbh.A&PDB-ENSP_mappings:5wbh.B&PDB-ENSP_mappings:5wbh.C&PDB-ENSP_mappings:5wbh.D&PDB-ENSP_mappings:5wbh.E&PDB-ENSP_mappings:5wbu.A&PDB-ENSP_mappings:5wbu.B&PDB-ENSP_mappings:5wby.A&PDB-ENSP_mappings:5wby.B&PDB-ENSP_mappings:5zcs.A&PDB-ENSP_mappings:5zcs.B&PDB-ENSP_mappings:6bcu.A&PDB-ENSP_mappings:6bcu.B&PDB-ENSP_mappings:6bcx.A&PDB-ENSP_mappings:6bcx.B&PDB-ENSP_mappings:6m4u.B&PDB-ENSP_mappings:6m4u.F&PDB-ENSP_mappings:6m4w.G&PDB-ENSP_mappings:6m4w.H&PDB-ENSP_mappings:6m4w.I&PDB-ENSP_mappings:6sb0.A&PDB-ENSP_mappings:6sb0.B&PDB-ENSP_mappings:6sb2.A&PDB-ENSP_mappings:6sb2.B&PDB-ENSP_mappings:6zwm.A&PDB-ENSP_mappings:6zwm.B&PDB-ENSP_mappings:6zwo.B&PDB-ENSP_mappings:7epd.B&PDB-ENSP_mappings:7owg.B&PDB-ENSP_mappings:7pe7.A&PDB-ENSP_mappings:7pe7.B&PDB-ENSP_mappings:7pe8.A&PDB-ENSP_mappings:7pe9.A&PDB-ENSP_mappings:7pea.A&PDB-ENSP_mappings:7pea.B&PDB-ENSP_mappings:7peb.A&PDB-ENSP_mappings:7pec.A&PDB-ENSP_mappings:7tzo.A&PDB-ENSP_mappings:7tzo.B&PDB-ENSP_mappings:7uxc.A&PDB-ENSP_mappings:7uxh.A&PDB-ENSP_mappings:7uxh.C&PDB-ENSP_mappings:8er6.B&PDB-ENSP_mappings:8er6.D&PDB-ENSP_mappings:8er6.F&PDB-ENSP_mappings:8er7.B&PDB-ENSP_mappings:8er7.D&PDB-ENSP_mappings:8er7.F&PDB-ENSP_mappings:8era.A&PDB-ENSP_mappings:8ppz.B&PDB-ENSP_mappings:8xi9.A&PDB-ENSP_mappings:9f44.A&PDB-ENSP_mappings:9f44.B&PDB-ENSP_mappings:9f45.A&PDB-ENSP_mappings:9f45.B&SMART:SM01345&Pfam:PF08771&Gene3D:1.20.120.150&Superfamily:SSF47212&PANTHER:PTHR11139&AFDB-ENSP_mappings:AF-P42345-F1																																									FAIL	-32	32	22	-3	0	0	0	0	MTOR	0.676	2.68E-01																																																										4				1							250	v6.0	Unknown	TRUE	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"MTOR","entrezGeneId":2475,"alteration":"ENSP00000354558.4:P2053L","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.","variantSummary":"The MTOR ENSP00000354558.4:p2053l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:P2053L mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"01/16/2019"}	01/16/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:P2053L mutant UNKNOWN.	FALSE	The MTOR ENSP00000354558.4:p2053l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	11187739				
chr1	11130772	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:49.21:0,6:1:0,0:0,6:6:GCC:0,0,3,3:0,0,3,3	NM_004958	T	stop_gained	HIGH	MTOR	ENSG00000198793	Transcript	ENST00000361445	protein_coding	39/58		ENST00000361445.9:c.5370G>A	ENSP00000354558.4:p.Trp1790Ter	5491	5370	1790	W/*	tgG/tgA	rs2100433455		-1		SNV	HGNC	HGNC:3942	YES	MANE_Select	NM_004958.4		1	P1	CCDS127.1	ENSP00000354558	P42345.237		UPI000012ABD3			1			PDB-ENSP_mappings:3jbz.A&PDB-ENSP_mappings:4jsn.A&PDB-ENSP_mappings:4jsn.B&PDB-ENSP_mappings:4jsp.A&PDB-ENSP_mappings:4jsp.B&PDB-ENSP_mappings:4jsv.A&PDB-ENSP_mappings:4jsv.B&PDB-ENSP_mappings:4jsx.A&PDB-ENSP_mappings:4jsx.B&PDB-ENSP_mappings:4jt5.A&PDB-ENSP_mappings:4jt5.B&PDB-ENSP_mappings:4jt6.A&PDB-ENSP_mappings:4jt6.B&PDB-ENSP_mappings:5flc.B&PDB-ENSP_mappings:5flc.F&PDB-ENSP_mappings:5h64.A&PDB-ENSP_mappings:5h64.a&PDB-ENSP_mappings:5wbu.A&PDB-ENSP_mappings:5wbu.B&PDB-ENSP_mappings:5wby.A&PDB-ENSP_mappings:5wby.B&PDB-ENSP_mappings:5zcs.A&PDB-ENSP_mappings:5zcs.B&PDB-ENSP_mappings:6bcu.A&PDB-ENSP_mappings:6bcu.B&PDB-ENSP_mappings:6bcx.A&PDB-ENSP_mappings:6bcx.B&PDB-ENSP_mappings:6sb0.A&PDB-ENSP_mappings:6sb0.B&PDB-ENSP_mappings:6sb2.A&PDB-ENSP_mappings:6sb2.B&PDB-ENSP_mappings:6zwm.A&PDB-ENSP_mappings:6zwm.B&PDB-ENSP_mappings:6zwo.B&PDB-ENSP_mappings:7owg.B&PDB-ENSP_mappings:7pe7.A&PDB-ENSP_mappings:7pe7.B&PDB-ENSP_mappings:7pe8.A&PDB-ENSP_mappings:7pe9.A&PDB-ENSP_mappings:7pea.A&PDB-ENSP_mappings:7pea.B&PDB-ENSP_mappings:7peb.A&PDB-ENSP_mappings:7pec.A&PDB-ENSP_mappings:7tzo.A&PDB-ENSP_mappings:7tzo.B&PDB-ENSP_mappings:7uxc.A&PDB-ENSP_mappings:7uxh.A&PDB-ENSP_mappings:7uxh.C&PDB-ENSP_mappings:8era.A&PDB-ENSP_mappings:9f44.A&PDB-ENSP_mappings:9f44.B&PDB-ENSP_mappings:9f45.A&PDB-ENSP_mappings:9f45.B&PROSITE_profiles:PS51189&Pfam:PF02259&Gene3D:1.25.40.10&PANTHER:PTHR11139&AFDB-ENSP_mappings:AF-P42345-F1									0	0	0	0	0	0	0	0	0	0												0	gnomADe_AFR&gnomADe_AMR&gnomADe_ASJ&gnomADe_EAS&gnomADe_FIN&gnomADe_MID&gnomADe_NFE&gnomADe_REMAINING&gnomADe_SAS										FAIL	-14	40	3	-14	0	0	0	0	MTOR		2.68E-01																																																										6				1							250	v6.0	Unknown	TRUE	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"MTOR","entrezGeneId":2475,"alteration":"ENSP00000354558.4:W1790*","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in various cancer types.","variantSummary":"The MTOR ENSP00000354558.4:w1790* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:W1790* mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"01/16/2019"}	01/16/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR ENSP00000354558.4:W1790* mutant UNKNOWN.	FALSE	The MTOR ENSP00000354558.4:w1790* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	11190829				
chr1	15872862	.	G	GGAAAAAATA	.	PASS	GT:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:26.19:4,3:0.429:2,3:2,0:7:TGA:2,2,1,2:2,2,1,2	NM_015001	GAAAAAATA	protein_altering_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Feb-15		ENST00000375759.8:c.130_131insGAAAAAATA	ENSP00000364912.3:p.Glu44delinsGlyLysAsnLys	491-492	130-131	44	E/GKNK	gaa/gGAAAAAATAaa			1		insertion	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1			Gene3D:3.30.70.330&Pfam:PF00076&PROSITE_profiles:PS50102&SMART:SM00360&Superfamily:SSF54928&CDD:cd12348																																																				9.40E-02																																																										7				1							239.82	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:E44delinsGKNK","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:e44delinsGKNK alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:E44delinsGKNK altered UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:E44delinsGKNK altered UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:e44delinsGKNK alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16199357				
chr1	15909380	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:42.17:0,4:1:0,0:0,4:4:GCA:0,0,1,3:0,0,3,1	NM_015001	T	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Apr-15		ENST00000375759.8:c.941C>T	ENSP00000364912.3:p.Ala314Val	1302	941	314	A/V	gCa/gTa	rs2148728241		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	deleterious(0)	probably_damaging(0.958)	PANTHER:PTHR23189&Superfamily:SSF54928&MobiDB_lite:mobidb-lite																																									FAIL	-47	-21	-14	-41	0	0	0	0	SPEN	0.208	9.40E-02																																																										4				1							167.81	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:A314V","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:a314v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A314V mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A314V mutant UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:a314v mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16235875				
chr1	15932468	.	G	GAAAAAT	.	PASS	GT:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB:PS	0|1:7.5:7,3:0.3:7,0:0,3:10:AGA:3,4,1,2:3,4,2,1:16258963	NM_015001	AAAAAT	inframe_insertion	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Nov-15		ENST00000375759.8:c.6229_6230insAAAATA	ENSP00000364912.3:p.Lys2076_Arg2077insLysAsn	6589-6590	6228-6229	2076-2077	-/KN	-/AAAAAT			1		insertion	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1			Pfam:PF20809&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg		1																																																		9.40E-02																																																										10				1							217.82	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:K2076_R2077insKN","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:k2076_r2077insKN alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:K2076_R2077insKN altered UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:K2076_R2077insKN altered UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:k2076_r2077insKN alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16258963				
chr1	15932470	.	G	GAA	.	PASS	GT:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB:PS	0|1:8.31:7,3:0.3:7,0:0,3:10:AGA:3,4,1,2:3,4,2,1:16258963	NM_015001	AA	frameshift_variant	HIGH	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Nov-15		ENST00000375759.8:c.6231_6232insAA	ENSP00000364912.3:p.Gly2078LysfsTer9	6591-6592	6230-6231	2077	R/RX	aga/agAAa			1		insertion	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1			Pfam:PF20809&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg		1																																																		9.40E-02																																																										10				1							217.82	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:G2078Kfs*9","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:g2078kfs*9 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:G2078Kfs*9 mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:G2078Kfs*9 mutant UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:g2078kfs*9 mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16258965				
chr1	15932472	.	G	A	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB:PS	0|1:0.00:0.00:0.00:9.55:7,3:0.3:7,0:0,3:10:AGG:2,5,2,1:2,5,1,2:16258963	NM_015001	A	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Nov-15		ENST00000375759.8:c.6232G>A	ENSP00000364912.3:p.Gly2078Arg	6593	6232	2078	G/R	Gga/Aga			1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	tolerated(0.08)	probably_damaging(0.998)	Pfam:PF20809&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg																																									FAIL	-41	20	19	-49	0	0	0	0	SPEN	0.108	9.40E-02																																																										10				1							217.82	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:G2078R","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:g2078r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:G2078R mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:G2078R mutant UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:g2078r mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16258967				
chr1	15935587	.	C	A	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:34.54:0,3:1:0,0:0,3:3:GCG:0,0,3,0:0,0,0,3	NM_015001	A	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Nov-15		ENST00000375759.8:c.9347C>A	ENSP00000364912.3:p.Ala3116Glu	9708	9347	3116	A/E	gCg/gAg	COSV65359979		1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	deleterious(0)	benign(0.035)																																		1	1							FAIL	-14	29	43	44	0	0	0.01	0	SPEN	0.023	9.40E-02																																																										3				1							250	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:A3116E","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:a3116e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A3116E mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:A3116E mutant UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:a3116e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16262082				
chr1	15937197	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:30.56:4,5:0.556:0,0:4,5:9:CCT:2,2,4,1:2,2,1,4	NM_015001	T	missense_variant	MODERATE	SPEN	ENSG00000065526	Transcript	ENST00000375759	protein_coding	Dec-15		ENST00000375759.8:c.10061C>T	ENSP00000364912.3:p.Pro3354Leu	10422	10061	3354	P/L	cCt/cTt			1		SNV	HGNC	HGNC:17575	YES	MANE_Select	NM_015001.3		1	P1	CCDS164.1	ENSP00000364912	Q96T58.212		UPI000006FF0C			1	tolerated(0.35)	benign(0)	MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg																																									FAIL	-34	-4	-18	-19	0	0	0	0	SPEN	0.064	9.40E-02																																																										9				1							247.15	v6.0	Unknown	TRUE	SPEN encodes a tumor suppressor that regulates transcription of ERÎ±-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SPEN","entrezGeneId":23013,"alteration":"ENSP00000364912.3:P3354L","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SPEN encodes a tumor suppressor that regulates transcription of ER\u03b1-target genes and has been associated with tumor growth inhibition. Somatic mutations and loss of heterozygosity of SPEN have been found in breast cancer.","variantSummary":"The SPEN ENSP00000364912.3:p3354l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:P3354L mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"05/11/2017"}	05/11/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SPEN ENSP00000364912.3:P3354L mutant UNKNOWN.	FALSE	The SPEN ENSP00000364912.3:p3354l mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	16263692				
chr1	17027755	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:20.13:3,3:0.5:3,3:0,0:6:TCT:1,2,0,3:1,2,0,3	NM_003000	T	synonymous_variant	LOW	SDHB	ENSG00000117118	Transcript	ENST00000375499	protein_coding	05-Aug		ENST00000375499.8:c.534G>A	ENSP00000364649.3:p.Glu178%3D	547	534	178	E	gaG/gaA	rs2077999274		-1		SNV	HGNC	HGNC:10681	YES	MANE_Select	NM_003000.3		1	P1	CCDS176.1	ENSP00000364649	P21912.247		UPI0000129380			1			Gene3D:1.10.1060.10&PDB-ENSP_mappings:8gs8.B&AFDB-ENSP_mappings:AF-P21912-F1&Phobius:NON_CYTOPLASMIC_DOMAIN&PROSITE_profiles:PS51379&PANTHER:PTHR11921&Superfamily:SSF46548&NCBIFAM:TIGR00384									7.05E-07	0	0	0	0	0	0	9.32E-07	0	0												9.32E-07	gnomADe_NFE	likely_benign		1							FAIL	-41	5	-6	5	0	0	0.05	0.47	SDHB		7.41E-01	1130341				1109693	Hereditary_cancer-predisposing_syndrome&Pheochromocytoma&Gastrointestinal_stromal_tumor&Pheochromocytoma/paraganglioma_syndrome_4		MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&Human_Phenotype_Ontology:HP:0002666&MONDO:MONDO:0008233&MedGen:C0031511&OMIM:171300&Orphanet:29072&Human_Phenotype_Ontology:HP:0100723&MONDO:MONDO:0011719&MeSH:D046152&MedGen:C0238198&OMIM:606764&Orphanet:44890&MONDO:MONDO:0007273&MedGen:C1861848&OMIM:115310&Orphanet:29072		NC_000001.11:g.17027755C>T	criteria_provided&_multiple_submitters&_no_conflicts	Likely_benign			SCV001667753&SCV002646292	single_nucleotide_variant	SO:0001483	ClinGen:CA416085665		SDHB:6390	SO:0001819&synonymous_variant										1	2077999274																										6				1							250	v6.0	Unknown	TRUE	SDHB, a subunit of succinate dehydrogenase, is infrequently altered in cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SDHB","entrezGeneId":6390,"alteration":"ENSP00000364649.3:E178%3D","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SDHB, a subunit of succinate dehydrogenase, is infrequently altered in cancer.","variantSummary":"The SDHB ENSP00000364649.3:e178%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHB ENSP00000364649.3:E178%3D mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"04/15/2025"}	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHB ENSP00000364649.3:E178%3D mutant UNKNOWN.	FALSE	The SDHB ENSP00000364649.3:e178%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	17354250				
chr1	17054002	.	G	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:38.5:0,3:1:0,2:0,1:3:GGG:0,0,1,2:0,0,2,1	NM_003000	T	synonymous_variant	LOW	SDHB	ENSG00000117118	Transcript	ENST00000375499	protein_coding	01-Aug		ENST00000375499.8:c.18C>A	ENSP00000364649.3:p.Ala6%3D	31	18	6	A	gcC/gcA	rs2746462&COSV108226518		-1		SNV	HGNC	HGNC:10681	YES	MANE_Select	NM_003000.3		1	P1	CCDS176.1	ENSP00000364649	P21912.247		UPI0000129380			1			PDB-ENSP_mappings:8gs8.B&AFDB-ENSP_mappings:AF-P21912-F1&Phobius:SIGNAL_PEPTIDE&Phobius:SIGNAL_PEPTIDE_N_REGION&SignalP_GRAM_POSITIVE:SignalP-TM			0.9571	0.8797	0.9769	0.996	0.9722	0.9918	0.9738	0.9099	0.9816	0.9545	0.9876	0.9785	0.9648	0.9742	0.9715	0.9881	0.956	0.9076	0.9342	0.9706	0.953	0.9959	0.9791	0.983	0.9735	0.9522	0.9913	0.996	EAS	benign	0&1	1&1	25741868&24033266&23757202&32022527&32708070						FAIL	25	-12	42	0	0	0	0	0	SDHB		7.41E-01	44641	0.95147		0.95707	53808	Pheochromocytoma&Gastrointestinal_stromal_tumor&Pheochromocytoma/paraganglioma_syndrome_4&Mitochondrial_complex_2_deficiency&_nuclear_type_4&Hereditary_cancer-predisposing_syndrome&not_specified&not_provided&Hereditary_pheochromocytoma-paraganglioma&Carney-Stratakis_syndrome		Human_Phenotype_Ontology:HP:0002666&MONDO:MONDO:0008233&MedGen:C0031511&OMIM:171300&Orphanet:29072&Human_Phenotype_Ontology:HP:0100723&MONDO:MONDO:0011719&MeSH:D046152&MedGen:C0238198&OMIM:606764&Orphanet:44890&MONDO:MONDO:0007273&MedGen:C1861848&OMIM:115310&Orphanet:29072&MONDO:MONDO:0030974&MedGen:C5543176&OMIM:619224&MONDO:MONDO:0015356&MeSH:D009386&MedGen:C0027672&Orphanet:140162&MedGen:CN169374&MedGen:C3661900&MONDO:MONDO:0017366&MedGen:C1708353&OMIM:PS168000&Orphanet:29072&MONDO:MONDO:0011740&MedGen:C1847319&OMIM:606864&Orphanet:97286		NC_000001.11:g.17054002G>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV000061379&SCV000111937&SCV000212792&SCV000309327&SCV000351449&SCV000351450&SCV000605076&SCV000611713&SCV001733274&SCV001840405&SCV002054691&SCV002054692&SCV002054693&SCV002054694&SCV004015413&SCV004362287&SCV005285520&SCV006089852&SCV006099520	single_nucleotide_variant	SO:0001483	ClinGen:CA015571		SDHB:6390	SO:0001819&synonymous_variant										1	2746462																										3				1							250	v6.0	Unknown	TRUE	SDHB, a subunit of succinate dehydrogenase, is infrequently altered in cancer.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"SDHB","entrezGeneId":6390,"alteration":"ENSP00000364649.3:A6%3D","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"SDHB, a subunit of succinate dehydrogenase, is infrequently altered in cancer.","variantSummary":"The SDHB ENSP00000364649.3:a6%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHB ENSP00000364649.3:A6%3D mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"04/15/2025"}	04/15/2025	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SDHB ENSP00000364649.3:A6%3D mutant UNKNOWN.	FALSE	The SDHB ENSP00000364649.3:a6%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	17380497				
chr1	18636310	.	G	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:38.19:0,4:1:0,4:0,0:4:AGA:0,0,4,0:0,0,4,0	NM_001135254	T	missense_variant	MODERATE	PAX7	ENSG00000009709	Transcript	ENST00000420770	protein_coding	04-Sep		ENST00000420770.7:c.525G>T	ENSP00000403389.2:p.Lys175Asn	1283	525	175	K/N	aaG/aaT			1		SNV	HGNC	HGNC:8621	YES	MANE_Select	NM_001135254.2		1	P1	CCDS44074.1	ENSP00000403389	P23759.221		UPI0000E1E6AE	P23759-3		1	deleterious_low_confidence(0)	benign(0.01)	AFDB-ENSP_mappings:AF-P23759-F1&PANTHER:PTHR45636&MobiDB_lite:mobidb-lite&MobiDB_lite:mobidb-lite&Low_complexity_(Seg):seg																																									FAIL	4	-42	5	27	0	0	0	0	PAX7	0.347	5.04E-01																																																										4				1							250	v6.0	Unknown	TRUE	PAX7, a transcription factor, is altered by chromosomal translocation in rhabdomyosarcoma.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"PAX7","entrezGeneId":5081,"alteration":"ENSP00000403389.2:K175N","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"PAX7, a transcription factor, is altered by chromosomal translocation in rhabdomyosarcoma.","variantSummary":"The PAX7 ENSP00000403389.2:k175n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX7 ENSP00000403389.2:K175N mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"11/20/2023"}	11/20/2023	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PAX7 ENSP00000403389.2:K175N mutant UNKNOWN.	FALSE	The PAX7 ENSP00000403389.2:k175n mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	18962804				
chr1	18748666	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:45.23:0,6:1:0,1:0,5:6:ACG:0,0,6,0:0,0,1,5	NM_001135254	T	3_prime_UTR_variant	MODIFIER	PAX7	ENSG00000009709	Transcript	ENST00000420770	protein_coding	09-Sep		ENST00000420770.7:c.*3737C>T		6013					rs1931548989		1		SNV	HGNC	HGNC:8621	YES	MANE_Select	NM_001135254.2		1	P1	CCDS44074.1	ENSP00000403389	P23759.221		UPI0000E1E6AE	P23759-3		1												3.76E-05	0	0	0	0	0	0	6.09E-05	0	0	6.58E-06	2.42E-05	0	0	0	0	0	0	0	0	0	6.09E-05	gnomADe_NFE										FAIL	6	-33	-14	-4	0	0	0	0	PAX7		5.04E-01																																																										6				1							238.66													chr1	19075160				
chr1	26779030	.	G	A	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:1.00:18.03:11,3:0.214:7,3:4,0:14:GGG:5,6,2,1:5,6,2,1	NM_006015	A	missense_variant	MODERATE	ARID1A	ENSG00000117713	Transcript	ENST00000324856	protein_coding	20/20		ENST00000324856.13:c.5132G>A	ENSP00000320485.7:p.Gly1711Glu	5521	5132	1711	G/E	gGg/gAg	rs2081164007&COSV61371384		1		SNV	HGNC	HGNC:11110	YES	MANE_Select	NM_006015.6		1	A2	CCDS285.1	ENSP00000320485	O14497.225		UPI0000167B91	O14497-1		1	deleterious_low_confidence(0)		PDB-ENSP_mappings:6lth.L&PDB-ENSP_mappings:6ltj.L&AFDB-ENSP_mappings:AF-O14497-F1&PANTHER:PTHR12656																																	0&1	0&1							FAIL	-7	0	1	0	0	0.01	0	0	ARID1A	0.432	1.41E-01																																																										14				1							245.25	v6.0	Unknown	TRUE	ARID1A, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation in various cancer types including endometrial and bladder cancers.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"ARID1A","entrezGeneId":8289,"alteration":"ENSP00000320485.7:G1711E","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"ARID1A, a tumor suppressor involved in transcriptional regulation, is inactivated by mutation in various cancer types including endometrial and bladder cancers.","variantSummary":"The ARID1A ENSP00000320485.7:g1711e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1A ENSP00000320485.7:G1711E mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"01/31/2018"}	01/31/2018	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ARID1A ENSP00000320485.7:G1711E mutant UNKNOWN.	FALSE	The ARID1A ENSP00000320485.7:g1711e mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	27105521				
chr1	39900588	.	G	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:56.58:0,9:1:0,2:0,7:9:AGC:0,0,4,5:0,0,5,4	NM_001033081	T	intron_variant	MODIFIER	MYCL	ENSG00000116990	Transcript	ENST00000372816	protein_coding		01-Jan	ENST00000372816.3:c.496+351C>A							rs144862690		-1		SNV	HGNC	HGNC:7555	YES	MANE_Select	NM_001033081.3		2	A1	CCDS30682.1	ENSP00000361903	P12524.206		UPI000013EF27	P12524-1		1						0.0038	0.0008	0	0	0.0139	0.0041	0.005403	0.0003098	0.001674	0.004466	4.08E-05	0.02168	0.005274	0.005286	0.004752	0.008083	0.006081	0.0006265	0	0.003073	0.006624	0	0.02454	0.003401	0.007812	0.001903	0.006855	0.02454	gnomADg_FIN										FAIL	-38	-19	-25	-19	0	0.01	0	0	MYCL		6.17E-01																																																										9				1							248.59													chr1	40366260				
chr1	46055845	.	G	A	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:34.53:0,3:1:0,3:0,0:3:TGC:0,0,3,0:0,0,3,0	NM_003629	A	synonymous_variant	LOW	PIK3R3	ENSG00000117461	Transcript	ENST00000262741	protein_coding	07-Oct		ENST00000262741.10:c.891C>T	ENSP00000262741.5:p.Ser297%3D	1568	891	297	S	agC/agT	rs785468&COSV53105695&COSV53111169		-1		SNV	HGNC	HGNC:8981	YES	MANE_Select	NM_003629.4		1	P1	CCDS529.1	ENSP00000262741	Q92569.199		UPI000013D318	Q92569-1					Pfam:PF16454&Gene3D:1.10.287.1490&Prints:PR00678&AFDB-ENSP_mappings:AF-Q92569-F1			0.638	0.5893	0.6254	0.6885	0.7336	0.5624	0.6959	0.595	0.6562	0.7017	0.6852	0.7331	0.6323	0.7059	0.6873	0.616	0.6733	0.6053	0.6987	0.6688	0.7083	0.6661	0.7433	0.6054	0.7084	0.6594	0.6079	0.7433	gnomADg_FIN		0&1&1	0&1&1	36535266						FAIL	-22	0	-48	-50	0	0	0	0	PIK3R3		1.54E+00																																																										3				1							250	v6.0	Unknown	TRUE	PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"PIK3R3","entrezGeneId":8503,"alteration":"ENSP00000262741.5:S297%3D","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"PIK3R3 encodes a kinase involved in insulin-like growth factor 1 receptor signaling. Inactivating mutations of PIK3R3 are found in stomach and uterine cancers.","variantSummary":"The PIK3R3 ENSP00000262741.5:s297%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:S297%3D mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"03/22/2017"}	03/22/2017	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3R3 ENSP00000262741.5:S297%3D mutant UNKNOWN.	FALSE	The PIK3R3 ENSP00000262741.5:s297%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	46521517				
chr1	64834637	.	T	TGATTTTGCAGCGGCTGGTACCGGTTGTTCCTTTCCATGTTTAGCGC	.	PASS	GT:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:38.11:0,4:1:0,4:0,0:4:ATT:0,0,3,1:0,0,3,1	NM_002227	GATTTTGCAGCGGCTGGTACCGGTTGTTCCTTTCCATGTTTAGCGC	inframe_insertion&stop_retained_variant	MODERATE	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	25/25		ENST00000342505.5:c.3389_3390insGCGCTAAACATGGAAAGGAACAACCGGTACCAGCCGCTGCAAAATC	ENSP00000343204.4:p.Lys1130_Cys1131insArgTer	3683-3684	3389-3390	1130	K/KR*TWKGTTGTSRCKIX	aaa/aaGCGCTAAACATGGAAAGGAACAACCGGTACCAGCCGCTGCAAAATCa			-1		insertion	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			Gene3D:1.10.510.10&PDB-ENSP_mappings:3eyg.A&PDB-ENSP_mappings:3eyh.A&PDB-ENSP_mappings:4e4l.A&PDB-ENSP_mappings:4e4l.B&PDB-ENSP_mappings:4e4l.D&PDB-ENSP_mappings:4e4l.E&PDB-ENSP_mappings:4e4n.A&PDB-ENSP_mappings:4e4n.B&PDB-ENSP_mappings:4e5w.A&PDB-ENSP_mappings:4e5w.B&PDB-ENSP_mappings:4ehz.A&PDB-ENSP_mappings:4ehz.B&PDB-ENSP_mappings:4ehz.C&PDB-ENSP_mappings:4ehz.D&PDB-ENSP_mappings:4ei4.A&PDB-ENSP_mappings:4ei4.B&PDB-ENSP_mappings:4fk6.A&PDB-ENSP_mappings:4fk6.B&PDB-ENSP_mappings:4i5c.A&PDB-ENSP_mappings:4i5c.B&PDB-ENSP_mappings:4ivb.A&PDB-ENSP_mappings:4ivb.B&PDB-ENSP_mappings:4ivc.A&PDB-ENSP_mappings:4ivc.B&PDB-ENSP_mappings:4ivd.A&PDB-ENSP_mappings:4ivd.B&PDB-ENSP_mappings:4k6z.A&PDB-ENSP_mappings:4k77.A&PDB-ENSP_mappings:4k77.B&PDB-ENSP_mappings:5e1e.A&PDB-ENSP_mappings:5e1e.B&PDB-ENSP_mappings:5hx8.A&PDB-ENSP_mappings:5hx8.B&PDB-ENSP_mappings:5khw.A&PDB-ENSP_mappings:5khw.B&PDB-ENSP_mappings:5khx.A&PDB-ENSP_mappings:5wo4.A&PDB-ENSP_mappings:5wo4.B&PDB-ENSP_mappings:6aah.A&PDB-ENSP_mappings:6aah.B&PDB-ENSP_mappings:6bbu.A&PDB-ENSP_mappings:6c7y.A&PDB-ENSP_mappings:6dbn.A&PDB-ENSP_mappings:6elr.A&PDB-ENSP_mappings:6elr.B&PDB-ENSP_mappings:6ggh.A&PDB-ENSP_mappings:6ggh.B&PDB-ENSP_mappings:6hzu.A&PDB-ENSP_mappings:6hzu.B&PDB-ENSP_mappings:6n77.A&PDB-ENSP_mappings:6n77.B&PDB-ENSP_mappings:6n78.A&PDB-ENSP_mappings:6n79.A&PDB-ENSP_mappings:6n7a.A&PDB-ENSP_mappings:6n7a.B&PDB-ENSP_mappings:6n7b.A&PDB-ENSP_mappings:6n7c.A&PDB-ENSP_mappings:6n7c.B&PDB-ENSP_mappings:6n7d.A&PDB-ENSP_mappings:6rsb.A&PDB-ENSP_mappings:6rsb.B&PDB-ENSP_mappings:6rsc.A&PDB-ENSP_mappings:6rsc.B&PDB-ENSP_mappings:6rsd.A&PDB-ENSP_mappings:6rsd.B&PDB-ENSP_mappings:6rse.A&PDB-ENSP_mappings:6rse.B&PDB-ENSP_mappings:6rsh.A&PDB-ENSP_mappings:6rsh.B&PDB-ENSP_mappings:6sm8.A&PDB-ENSP_mappings:6sm8.B&PDB-ENSP_mappings:6smb.A&PDB-ENSP_mappings:6smb.B&PDB-ENSP_mappings:6tpe.A&PDB-ENSP_mappings:6tpe.B&PDB-ENSP_mappings:6tpf.A&PDB-ENSP_mappings:6tpf.B&PDB-ENSP_mappings:6w8l.A&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF07714&PIRSF:PIRSF000636&PROSITE_profiles:PS50011&PANTHER:PTHR45807&SMART:SM00219&Superfamily:SSF56112&CDD:cd05079																																																				1.68E-01																																																										5				0.8							84.07	v6.0	Unknown	TRUE	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"JAK1","entrezGeneId":3716,"alteration":"ENSP00000343204.4:K1130_C1131insR*","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.","variantSummary":"The JAK1 ENSP00000343204.4:k1130_c1131insr* alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1130_C1131insR* altered UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"02/04/2019"}	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1130_C1131insR* altered UNKNOWN.	FALSE	The JAK1 ENSP00000343204.4:k1130_c1131insr* alteration has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65300320				
chr1	64837976	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:45.77:0,5:1:0,5:0,0:5:CCT:0,0,2,3:0,0,2,3	NM_002227	T	synonymous_variant	LOW	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	22/25		ENST00000342505.5:c.3096G>A	ENSP00000343204.4:p.Lys1032%3D	3390	3096	1032	K	aaG/aaA	rs12129819&COSV53805030		-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			Gene3D:1.10.510.10&PDB-ENSP_mappings:3eyg.A&PDB-ENSP_mappings:3eyh.A&PDB-ENSP_mappings:4e4l.A&PDB-ENSP_mappings:4e4l.B&PDB-ENSP_mappings:4e4l.D&PDB-ENSP_mappings:4e4l.E&PDB-ENSP_mappings:4e4n.A&PDB-ENSP_mappings:4e4n.B&PDB-ENSP_mappings:4e5w.A&PDB-ENSP_mappings:4e5w.B&PDB-ENSP_mappings:4ehz.A&PDB-ENSP_mappings:4ehz.B&PDB-ENSP_mappings:4ehz.C&PDB-ENSP_mappings:4ehz.D&PDB-ENSP_mappings:4ei4.A&PDB-ENSP_mappings:4ei4.B&PDB-ENSP_mappings:4fk6.A&PDB-ENSP_mappings:4fk6.B&PDB-ENSP_mappings:4i5c.A&PDB-ENSP_mappings:4i5c.B&PDB-ENSP_mappings:4ivb.A&PDB-ENSP_mappings:4ivb.B&PDB-ENSP_mappings:4ivc.A&PDB-ENSP_mappings:4ivc.B&PDB-ENSP_mappings:4ivd.A&PDB-ENSP_mappings:4ivd.B&PDB-ENSP_mappings:4k6z.A&PDB-ENSP_mappings:4k77.A&PDB-ENSP_mappings:4k77.B&PDB-ENSP_mappings:5e1e.A&PDB-ENSP_mappings:5e1e.B&PDB-ENSP_mappings:5hx8.A&PDB-ENSP_mappings:5hx8.B&PDB-ENSP_mappings:5khw.A&PDB-ENSP_mappings:5khw.B&PDB-ENSP_mappings:5khx.A&PDB-ENSP_mappings:5wo4.A&PDB-ENSP_mappings:5wo4.B&PDB-ENSP_mappings:6aah.A&PDB-ENSP_mappings:6aah.B&PDB-ENSP_mappings:6bbu.A&PDB-ENSP_mappings:6c7y.A&PDB-ENSP_mappings:6dbn.A&PDB-ENSP_mappings:6elr.A&PDB-ENSP_mappings:6elr.B&PDB-ENSP_mappings:6ggh.A&PDB-ENSP_mappings:6ggh.B&PDB-ENSP_mappings:6hzu.A&PDB-ENSP_mappings:6hzu.B&PDB-ENSP_mappings:6n77.A&PDB-ENSP_mappings:6n77.B&PDB-ENSP_mappings:6n78.A&PDB-ENSP_mappings:6n79.A&PDB-ENSP_mappings:6n7a.A&PDB-ENSP_mappings:6n7a.B&PDB-ENSP_mappings:6n7b.A&PDB-ENSP_mappings:6n7c.A&PDB-ENSP_mappings:6n7c.B&PDB-ENSP_mappings:6n7d.A&PDB-ENSP_mappings:6rsb.A&PDB-ENSP_mappings:6rsb.B&PDB-ENSP_mappings:6rsc.A&PDB-ENSP_mappings:6rsc.B&PDB-ENSP_mappings:6rsd.A&PDB-ENSP_mappings:6rsd.B&PDB-ENSP_mappings:6rse.A&PDB-ENSP_mappings:6rse.B&PDB-ENSP_mappings:6rsh.A&PDB-ENSP_mappings:6rsh.B&PDB-ENSP_mappings:6sm8.A&PDB-ENSP_mappings:6sm8.B&PDB-ENSP_mappings:6smb.A&PDB-ENSP_mappings:6smb.B&PDB-ENSP_mappings:6tpe.A&PDB-ENSP_mappings:6tpe.B&PDB-ENSP_mappings:6tpf.A&PDB-ENSP_mappings:6tpf.B&PDB-ENSP_mappings:6w8l.A&PDB-ENSP_mappings:8exj.D&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF07714&PIRSF:PIRSF000636&PROSITE_profiles:PS50011&PANTHER:PTHR45807&SMART:SM00219&Superfamily:SSF56112&CDD:cd05079			0.0385	0.0219	0.0548	0	0.1153	0.0102	0.09158	0.03229	0.05718	0.09401	7.56E-05	0.1121	0.08287	0.1035	0.08189	0.01456	0.07615	0.03404	0.1099	0.07941	0.09343	0.0001926	0.1133	0.08844	0.104	0.08617	0.01222	0.1153	EUR	benign	0&1	1&1	23670291&36669486&26242990						FAIL	-2	-1	-2	-44	0	0	0	0	JAK1		1.68E-01	1168338	0.0806	0.07574	0.03854	1153650	not_provided		MedGen:C3661900		NC_000001.11:g.64837976C>T	criteria_provided&_multiple_submitters&_no_conflicts	Benign			SCV001727222&SCV005287336	single_nucleotide_variant	SO:0001483	ClinGen:CA892528		JAK1:3716	SO:0001819&synonymous_variant										1	12129819																										5				1							250	v6.0	Unknown	TRUE	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"JAK1","entrezGeneId":3716,"alteration":"ENSP00000343204.4:K1032%3D","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.","variantSummary":"The JAK1 ENSP00000343204.4:k1032%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1032%3D mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"02/04/2019"}	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:K1032%3D mutant UNKNOWN.	FALSE	The JAK1 ENSP00000343204.4:k1032%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65303659				
chr1	64844211	.	G	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:0.00:25.44:1,3:0.75:1,3:0,0:4:TGC:0,1,3,0:0,1,3,0	NM_002227	T	stop_gained	HIGH	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	17/25		ENST00000342505.5:c.2256C>A	ENSP00000343204.4:p.Cys752Ter	2550	2256	752	C/*	tgC/tgA			-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			Gene3D:1.10.510.10&PDB-ENSP_mappings:4l00.A&PDB-ENSP_mappings:4l00.B&PDB-ENSP_mappings:4l01.A&PDB-ENSP_mappings:4l01.B&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF07714&PIRSF:PIRSF000636&Prints:PR01823&PROSITE_profiles:PS50011&PANTHER:PTHR45807&SMART:SM00219&Superfamily:SSF56112&CDD:cd05077																																									FAIL	48	23	23	0	0	0	0	0	JAK1		1.68E-01																																																										4				1							250	v6.0	Unknown	TRUE	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"JAK1","entrezGeneId":3716,"alteration":"ENSP00000343204.4:C752*","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.","variantSummary":"The JAK1 ENSP00000343204.4:c752* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:C752* mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"02/04/2019"}	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:C752* mutant UNKNOWN.	FALSE	The JAK1 ENSP00000343204.4:c752* mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65309894				
chr1	64864883	.	C	T	.	PASS	GT:OBPa:OBParc:OBPsnp:SQ:AD:AF:F1R2:F2R1:DP:OBC:SB:MB	0/1:0.00:0.00:1.00:8.18:12,4:0.25:12,0:0,4:16:CCC:6,6,4,0:6,6,0,4	NM_002227	T	synonymous_variant	LOW	JAK1	ENSG00000162434	Transcript	ENST00000342505	protein_coding	Aug-25		ENST00000342505.5:c.1080G>A	ENSP00000343204.4:p.Arg360%3D	1374	1080	360	R	cgG/cgA	rs2101102515		-1		SNV	HGNC	HGNC:6190	YES	MANE_Select	NM_002227.4		5	A1	CCDS41346.1	ENSP00000343204	P23458.240		UPI0000054C7D			1			PDB-ENSP_mappings:5ixd.A&PDB-ENSP_mappings:5ixi.A&PDB-ENSP_mappings:5l04.A&AFDB-ENSP_mappings:AF-P23458-F1&Pfam:PF17887&PIRSF:PIRSF000636&PROSITE_profiles:PS50057&PANTHER:PTHR45807&CDD:cd13332																																									FAIL	26	5	-5	1	0	0	0	0	JAK1		1.68E-01																																																										16				1							238.78	v6.0	Unknown	TRUE	JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.	FALSE	{"query":{"id":null,"referenceGenome":"GRCh38","hugoSymbol":"JAK1","entrezGeneId":3716,"alteration":"ENSP00000343204.4:R360%3D","alterationType":null,"svType":null,"tumorType":"UNKNOWN","consequence":null,"proteinStart":null,"proteinEnd":null,"hgvs":null,"hgvsInfo":null,"canonicalTranscript":null},"geneExist":true,"variantExist":false,"alleleExist":false,"oncogenic":"Unknown","mutationEffect":{"knownEffect":"Unknown","description":"","citations":{"pmids":[],"abstracts":[]}},"highestSensitiveLevel":null,"highestResistanceLevel":null,"highestDiagnosticImplicationLevel":null,"highestPrognosticImplicationLevel":null,"highestFdaLevel":null,"otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"VUS":false,"hotspot":false,"exon":null,"geneSummary":"JAK1, an intracellular kinase, is frequently altered in hematologic malignancies and gynecological cancers.","variantSummary":"The JAK1 ENSP00000343204.4:r360%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.","tumorTypeSummary":"There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:R360%3D mutant UNKNOWN.","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[],"prognosticImplications":[],"treatments":[],"dataVersion":"v6.0","lastUpdate":"02/04/2019"}	02/04/2019	Unknown	MUTATION	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK1 ENSP00000343204.4:R360%3D mutant UNKNOWN.	FALSE	The JAK1 ENSP00000343204.4:r360%3d mutation has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.	chr1	65330566				
chr1	85270608	MantaBND:291:0:1:0:0:0:0	G	[chr14:24221114[G	.	PASS	PR	0,6	NM_003921	.G	feature_truncation&intron_variant	HIGH	BCL10	ENSG00000142867	Transcript	ENST00000648566	protein_coding		02-Feb										-1		chromosome_breakpoint	HGNC	HGNC:989	YES	MANE_Select	NM_003921.5			P1	CCDS704.1	ENSP00000498104	O95999.204		UPI000012682F			1																																																																																																														2		-19,20								TRUE		MantaBND:291:0:1:0:0:0:1	0														chr1	85736291			BND	

